First oral GLP‑1 pill approved
The FDA approved oral semaglutide as the first GLP‑1 pill for weight loss — a major expansion of treatment options beyond injectables. - That approval could shift weight‑loss strategies for people and influence gym recovery and training plans for those on GLP‑1 therapy. (ajmc.com)
The pivotal OASIS 4 phase‑3 program randomized 307 adults and, using a treatment‑policy analysis, found a mean weight reduction of about 13.6% at 64 weeks versus ~2% with placebo. (NEJM; OASIS 4). (nejm.org)) When analyzed for participants who adhered to the regimen, OASIS 4 reported an average weight loss near 16.6% at 64 weeks and showed roughly one‑third of treated patients lost ≥20% of body weight. (Company trial topline reporting; Applied Clinical Trials). (appliedclinicaltrialsonline.com)) Labeling and regulatory documents list the oral product at a 25 mg once‑daily target dose with a multi‑week escalation schedule used in trials, and the submission packages reference the cardiovascular outcomes evidence from the SELECT program. (FDA approval letter; Novo Nordisk press materials). (accessdata.fda.gov)) OASIS 4 safety data showed gastrointestinal adverse events were the most common: nausea occurred in about 46.6% of treated participants versus 18.6% on placebo, and vomiting in about 30.9% versus 5.9% on placebo, while reported serious adverse events were lower in the active arm than placebo. (OASIS 4 safety tables; company safety summaries). (ainvest.com)) Novo Nordisk announced production in U.S. facilities and signaled a full U.S. launch in early January 2026, with a promotional starting‑dose offering (1.5 mg starting pack) listed at $149 per month for qualifying cash‑pay patients and select telehealth channels. (Company news release; CNBC reporting). (novonordisk.mediaroom.com)) Regulatory filings for the oral 25 mg regimen were also submitted to the European Medicines Agency and other authorities in the second half of 2025, positioning the company to seek international approvals after the U.S. rollout. (Novo Nordisk regulatory filings; industry press). (biospace.com))
